Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Paladin Labs Inc Raises FY 2012 Revenue Guidance
Paladin Labs Inc announced that it expects to generate in excess of $200 million in revenue, of which at least $55 million is attributable to the consolidation of Litha. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $201 million for fiscal 2012.
Latest Developments for Paladin Labs Inc
- Paladin Labs Inc Announces Normal Course Issuer Bid And Automatic Share Purchase Plan
- Paladin Labs Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates
- Paladin Labs Inc Announces Canadian Approval For Silenor
- Paladin Labs Inc Names Jonathan Ross Goodman as Chairman of the Board of Directors
Latest Key Developments in Pharmaceuticals
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Share this
- Link this
- Digg this
Follow Reuters